Press Room

RDD Europe 2023

Start
Tuesday, May 02, 2023 - 09:00
End
Friday, May 05, 2023 - 17:06
Location: Antibes, France
Booth Number: Table #20
Drug Delivery Formulation | Hovione

Hovione will be exhibiting at RDD conference from May 2-5. Don’t miss the chance to speak with our experts in the Inspiring Dry Powder Inhalation Knowledge Space and learn how our development and manufacturing services for inhalation and nasal - integrated on a single site - can support in bringing your product to market.

 

Find us at the Blue Knowledge Space - Inspiring Dry Powder Inhalation - Table #20

 

schedule a meeting

 



 

 

On May 3rd, don’t miss the joint workshop with Hovione and H&T Presspart 

 

Title - “Integrated Development for Capsule-based DPIs - Solving New Challenges”

Presenters: 

  • Susana Saldanha, M.Sc. - R&D Manager, Formulation Development, Hovione
  • João Pereira, M.Sc. - R&D Analytical Development,  Analytical Manager, Hovione
  • Mirjam Kobler Ph.D. -  Global Business Development Manager, H&T Presspart 

Abstract:

This workshop will address the most relevant aspects of DPI development covering formulation to device development, as well as process optimization and analytical characterization.  The most common challenges expected at each stage will also be highlighted. A data-based development approach will be applied using risk analysis and structured experimental design based on various case studies, for different development stages, including process optimization and scale-up activities. Starting with a review on the design and development of a highly efficient capsule-based device, the participants will further learn how to use tools to prepare and design development plans to achieve optimal performance from different formulation strategies to drug-device combinations. Case studies will be presented on the interplay of carrier-based and carrier-free formulations, with a newly designed device. The higher focus will be placed on the hurdles of composite particles formulation and process development as well as capsule filling of said challenging formulations.  Unit operations such as spray drying and capsule filling will be covered during this workshop.

 

On May 4th, don’t miss the POP Session – “Posters on the podium” with Patricia Henriques, M.Sc.

 

Title - Benchmarking of Particle Engineering Strategies for Nasal Powder Delivery: Characterization of Nasal Deposition using the Alberta Idealized Nasal Inlet

 

Abstract:

Powder formulations of a drug and mucoadhesive polymer have increased residence time in the nasal cavity and can be manufactured by blending, spray-drying or agglomeration of primary particles into chimeral agglomerates (CA). While spray-drying allows particle size control and generation of amorphous solid dispersions, blending is simpler and CA should allow faster dissolution after breakup into smaller particles. The objective of this study was to characterize nasal deposition and benchmark nasal powders manufactured by different particle engineering strategies, namely spray dried microparticles (SDM), CA and blends, using the Alberta Idealized Nasal Inlet (AINI). The AINI method conditions were firstly optimized by selecting appropriate angle of actuation and flow rate. Then, six different formulations prepared with distinct polymers and particle engineering strategies were evaluated.

 

On May 5th, don’t miss the Podium Presentation with Eunice Costa R&D Director, Inhalation & Advanced Drug Delivery 

 

Title - “Addressing challenges in high dose dry powder inhalation: formulation and device”

 

Abstract:

High dose delivery to the lungs is gaining momentum to address a diversified array of diseases being treated via respiratory drug delivery, comprising a range of drug classes, spanning from less potent small molecules to biologics. Dry Powder Inhalers (DPI) are the dosage form of choice for delivering high payloads to patients. Still there are opportunities for improvement in terms of ensuring that the formulation addresses the pharmacokinetics needs of the specific drug and indication, in close integration with the device, while ensuring delivery efficiency and safety. 

Herein, different high dose delivery platform approaches are discussed in terms of relative advantages and potential pitfalls, followed by some exemplary case-studies: from small molecules to biologics: development of high dose crystalline formulations and high dose spray dried proteins, as well as implementation of a DPI device suitable for cohesive high dose formulations. 

 

 

Two posters will also be presented:

  • Title - In Vitro Methodologies for the Screening of Nasal Powders: Polymer-based Formulations 

    Presenter: Patricia Henriques, M.Sc. – University of Coimbra, Hovione

     
  • Title - Expediting spray dried DPI formulation via the use of PAT

    Presenter: Maria Inês Lopes, M.Sc. – University of Lisbon, Hovione

 

 

Schedule a meeting with our team and get to know more about our unique range of particle engineering technologies for Inhalation & Nasal such as jet milling, wet milling and spray drying.

Let’s discuss your project together.

schedule a meeting



 

 

 

 

Schedule a meeting with our experts.

Find more about RDD Europe.

 

 

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025